Effects of Intranasal Nerve Growth Factor for Traumatic Brain Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01212679|
Recruitment Status : Completed
First Posted : October 1, 2010
Last Update Posted : November 1, 2017
|Condition or disease||Intervention/treatment||Phase|
|Traumatic Brain Injury||Drug: nerve growth factor Drug: nomral saline||Phase 2|
Early NGF concentration in the cerebral spinal fluid(CSF)correlates significantly with the severity of head injury, and NGF upregulation correlates with better neurologic outcomes and could be useful to obtain clinical and prognostic information in patients with serve TBI.
However, the clinical use of NGF is difficulty associated with delivering them to the CNS because of the existing of blood-brain barrier(BBB). Intranasal delivery drug is a noninvasive and convenient novel method bypassing BBB, which results in targeting therapeutics to the CNS rapidly.
The proposed study is a randomized, double-blind, placebo-controlled trail of NGF, starting between 24 to 72 hours post TBI, continuing for 2 weeks.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||106 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Pilot Study of Intranasal Nerve Growth Factor for Traumatic Brain Injury(TBI)|
|Study Start Date :||December 2010|
|Actual Primary Completion Date :||October 2017|
|Actual Study Completion Date :||October 2017|
Experimental: nerve growth factor
Patients who underwent TBI will be chosen to receive NGF randomly.
Drug: nerve growth factor
The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
Placebo Comparator: Control
Patients who underwent TBI will be chosen to receive nomral saline randomly.
Drug: nomral saline
The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
- improved neurological functions [ Time Frame: at months 6 post-treatment ]Neurological functions will be assessed by GOS(Glasgow Outcome Scale), mRS(modified Rankin Scale),BI(Barthel index).
- HAMA,HAMD [ Time Frame: at months 6 post-treatment ]HAMA(Hamilton Anxiety Scale ),HAMD(Hamilton Depression Scale).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01212679
|Department of Neurology, Jinling Hospital, Nanjing University School of Medicine|
|Nanjing, Jiangsu, China, 210002|
|Study Chair:||Xinfeng Liu, MD||Department of Neurology, Jinling Hospital, Nanjing University School of Medicine|